Implementation of Physiotherapy on COVID-19 Patients in ICU

NCT04347070 | Unknown

• 1 other identifier: RECHMPL20_0175
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Despite new charachersitics of COVID-19 patients, critical care implementation seems to be similar to those with Acute Respiratory Distress Syndrome (ARDS) in intensive care units (ICU). Regarding the initial gravity of these patients, sedation and neuromuscular blockers are usually administrated, increasing the risk to develope an ICU-acquired weakness which is directly correlated to morbi-mortality and a burden during recovery. Respiratory symptoms are mostly related to dyspnoea and non-productive cough, with only 33% of COVID-19 patient having a bronchial hypersecretion ; consequently, chest physiotherapy is only implemented in after case-by-case evaluation. This unprecedented situation requires to identify how physiotherapy is being implemented in COVID-19 patients in ICU. This retrospective, multicentric study aims to identify the charactheristics of physiotherapy (type and time spent) implemented in Argentina, Belgium, Chili, France, Italy and Spain

Conditions

Sars-CoV2; COVID-19

Keywords

COVID-19; Physiotherapy; implementation; critical care

Outcome Measures

Primary Outcomes (3)

• Time of physiotherapy

  Time of physiotherapy (minutes)

  1 day

• Time of physiotherapy

  Time of physiotherapy (minutes)

  3 day

• Time of physiotherapy

  Time of physiotherapy (minutes)

  7 day

Secondary Outcomes (3)

• Type of physiotherapy implemented

  1 day

• Type of physiotherapy implemented

  3 day

• Type of physiotherapy implemented

  7 day

Study Arms (1)

Patients accepted in ICU diagnosed with COVID-19

Patients accepted in ICU diagnosed with COVID-19

Other: Phsyiotherapy

Interventions

Phsyiotherapy OTHER

To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time

Patients accepted in ICU diagnosed with COVID-19

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients admitted in ICU with COVID-19 will be eligible

You may qualify if:

• Age \> 18 years
• Patient admitted in ICU
• Patient with COVID-19 diagnosis

You may not qualify if:

• \- Explicite denie to participate in the study

Sponsors & Collaborators

• University Hospital, Montpellier: lead
• Société espagnole de pneumologie (SEPAR): collaborator
• Societe française de kinésithérapie en réanimation (SKR): collaborator

Study Sites (1)

Uhmontpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Roberto Martinez-Alejos, MD, PhD

  University Hospital, Montpellier

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 10, 2020
• First Posted: April 15, 2020
• Study Start: April 1, 2017
• Primary Completion: September 1, 2020
• Study Completion: December 1, 2022
• Last Updated: December 29, 2020

Record last verified: 2020-12

Locations

FR (1)